Ablynx grabs cheap €100m top-up from bond investors before window shuts
This article was originally published in Scrip
In the first significant return to the European bond market since Norwegian radiopharmaceutical specialist Algeta raised $120m back in September 2013, Belgian nanobody firm, Ablynx, has raised €100m ($110m) through a private placement of Senior Unsecured Convertible Bonds. According to CEO Edwin Moses, this provides Ablynx with "a lot more choice of how we spend our money, and options in product development." The bond route allowed Ablynx to raise its money rapidly and relatively cheaply.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.